Proteomics analysis of human mesenchymal stromal/stem cell sarcomagenesis model identifies ALDH1A3 and CD99 as potential targets in the transformation process


Por: Gobin, JM, Gao, J, Rey, V, Tornín, J, Muradia, G, Halabi, H, Bueno, C, Guerrero-Murillo, M, Lopez-Millan, B, Menendez, P, Rosu-Myles, M, Rodriguez, R and Lavoie, JR

Publicada: 9 ene 2026
Resumen:
BackgroundMesenchymal stromal/stem cells (MSC) may represent the cell-of-origin for sarcoma development. A collection of human MSCs sequentially mutated with an increasing number of oncogenic hits served to recreate a step-wise process of sarcomagenesis. To identify potential protein targets of interest in the MSC-sarcoma transformation process, quantitative mass spectrometry-based (LC-MS/MS) proteomics was performed.ResultsAmong the protein hits identified as significantly regulated in the transformation process, ALDH1A3 and CD99 were selected and further studied. Both ALDH1A3 abundance levels and activity were significantly upregulated in early-phase (immortalized) and fully transformed (sarcoma forming) cells as compared to normal MSCs. Inversely, CD99 total protein and cell-surface abundance levels were downregulated in immortalized and transformed MSCs. Downregulated CD99 was also identified in several human bone and soft tissue sarcoma subtypes.ConclusionsProteomics investigation of a MSC-transformation model of sarcoma has yielded ALDH1A3 and CD99 as potential targets for sarcomagenesis that may contribute to a greater understanding of the disease and the development of novel therapeutic approaches.

Filiaciones:
Gobin, JM:
 Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada

 Hlth Canada, Ctr Oncol Radiopharmaceut & Res, Hlth Prod & Food Branch, Biol & Radiopharmaceut Drugs Directorate, Ottawa, ON K1A 0K9, Canada

Gao, J:
 Hlth Canada, Ctr Oncol Radiopharmaceut & Res, Hlth Prod & Food Branch, Biol & Radiopharmaceut Drugs Directorate, Ottawa, ON K1A 0K9, Canada

Rey, V:
 Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33011, Spain

 Inst Univ Oncol Principado Asturias, Oviedo 33006, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain

Tornín, J:
 Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33011, Spain

 Inst Univ Oncol Principado Asturias, Oviedo 33006, Spain

Muradia, G:
 Hlth Canada, Ctr Oncol Radiopharmaceut & Res, Hlth Prod & Food Branch, Biol & Radiopharmaceut Drugs Directorate, Ottawa, ON K1A 0K9, Canada

Halabi, H:
 Hlth Canada, Ctr Oncol Radiopharmaceut & Res, Hlth Prod & Food Branch, Biol & Radiopharmaceut Drugs Directorate, Ottawa, ON K1A 0K9, Canada

:
 Univ Barcelona, Josep Carreras Leukaemia Res Inst, Sch Med, Dept Biomed, Barcelona, Spain

:
 Univ Barcelona, Josep Carreras Leukaemia Res Inst, Sch Med, Dept Biomed, Barcelona, Spain

Lopez-Millan, B:
 Univ Barcelona, Josep Carreras Leukaemia Res Inst, Sch Med, Dept Biomed, Barcelona, Spain

:
 Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain

 Univ Barcelona, Josep Carreras Leukaemia Res Inst, Sch Med, Dept Biomed, Barcelona, Spain

 Inst Salud Carlos III ISCII RICORS, Terapias Avanzadas TERAV, RD21 00170029, Madrid, Spain

 Inst Salud Carlos III ISCII RICORS, Red Espanola Terapias Avanzadas TERAV, RD21 0017 0029, Barcelona, Spain

Rosu-Myles, M:
 Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada

 Hlth Canada, Ctr Oncol Radiopharmaceut & Res, Hlth Prod & Food Branch, Biol & Radiopharmaceut Drugs Directorate, Ottawa, ON K1A 0K9, Canada

Rodriguez, R:
 Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33011, Spain

 Inst Univ Oncol Principado Asturias, Oviedo 33006, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain

Lavoie, JR:
 Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada

 Hlth Canada, Ctr Oncol Radiopharmaceut & Res, Hlth Prod & Food Branch, Biol & Radiopharmaceut Drugs Directorate, Ottawa, ON K1A 0K9, Canada
ISSN: 17417007





BMC Biology
Editorial
BioMed Central, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 24 Número: 1
Páginas:
WOS Id: 001682344200002
ID de PubMed: 41514266
imagen Green Submitted, gold

MÉTRICAS